DiaMedica Therapeutics
DMAC
28 hedge funds and large institutions have $3.92M invested in DiaMedica Therapeutics in 2022 Q4 according to their latest regulatory filings, with 5 funds opening new positions, 9 increasing their positions, 6 reducing their positions, and 3 closing their positions.
67% more first-time investments, than exits
New positions opened: 5 | Existing positions closed: 3
50% more repeat investments, than reductions
Existing positions increased: 9 | Existing positions reduced: 6
25% more capital invested
Capital invested by funds: $3.14M → $3.92M (+$787K)
8% more funds holding
Funds holding: 26 → 28 (+2)
0.02% less ownership
Funds ownership: 9.57% → 9.55% (-0.02%)
73% less call options, than puts
Call options by funds: $3K | Put options by funds: $11K
Top Buyers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
Renaissance Technologies
New York
|
+$45.3K |
| 2 |
Jane Street
New York
|
+$14.6K |
| 3 |
Citadel Advisors
Miami,
Florida
|
+$5.8K |
| 4 |
Northern Trust
Chicago,
Illinois
|
+$3.79K |
| 5 |
TRCT
Tower Research Capital (TRC)
New York
|
+$3.64K |
Top Sellers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
Susquehanna International Group
Bala Cynwyd,
Pennsylvania
|
-$44K |
| 2 |
Two Sigma Advisers
New York
|
-$31K |
| 3 |
HF
HRT Financial
New York
|
-$12K |
| 4 |
JAMONY
Jacob Asset Management of New York
Hermosa Beach,
California
|
-$6.42K |
| 5 |
UBS Group
Zurich,
Switzerland
|
-$4.63K |
| Name | Holding | Trade Value |
Shares Change |
Change in Stake |
|
|---|---|---|---|---|---|
26
Wells Fargo
San Francisco,
California
| $174 | +$4 | +3 | +3% |
|
27
Dimensional Fund Advisors
Austin,
Texas
| $68 | – | – | – |
|
28
Bank of America
Charlotte,
North Carolina
| $64 | +$54 | +40 | New |
|
|
29
Susquehanna International Group
Bala Cynwyd,
Pennsylvania
| – | -$44K | -35,258 | Closed |
|
|
30
Two Sigma Advisers
New York
| – | -$31K | -24,900 | Closed |
|
|
HF
31
HRT Financial
New York
| – | -$12K | -10,441 | Closed |
|
DMAC Hedge Fund Activity: Q4 2022 in Review
28 of the 6,221 institutional investors tracked by Wall St. Rank reported a position in DiaMedica Therapeutics (DMAC) for Q4 2022, worth a combined $3.92M — up 25% from $3.14M a quarter earlier.
Buyers outnumbered sellers: 5 funds opened new DMAC positions and 3 closed out — a net gain of 2 holders — while 9 added to existing stakes and 6 trimmed.
The largest buyer was Renaissance Technologies, opening a new position worth an estimated $45.3K. The largest seller was Susquehanna International Group, exiting entirely with an estimated $44K sold.
- 28 institutional investors held DiaMedica Therapeutics (DMAC) as of Q4 2022, up from 26 in Q3 2022.
- Funds reported $3.92M of DiaMedica Therapeutics stock for Q4 2022, up 25% quarter-over-quarter.
- 5 funds opened new DiaMedica Therapeutics positions in Q4 2022 and 3 closed out, a net change of +2 holders.
- The largest DiaMedica Therapeutics buyer in Q4 2022 was Renaissance Technologies, an estimated $45.3K added.
- The largest DiaMedica Therapeutics seller in Q4 2022 was Susquehanna International Group, an estimated $44K sold.
Based on aggregated 13F filings for Q4 2022.